Debashis Ghosh
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1755 | 5.030 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 364 | 4.530 |
Why?
| | Models, Statistical | 44 | 2024 | 667 | 4.500 |
Why?
| | Leishmaniasis, Visceral | 16 | 2024 | 22 | 4.380 |
Why?
| | Algorithms | 41 | 2025 | 1718 | 4.160 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 760 | 3.360 |
Why?
| | Computer Simulation | 36 | 2024 | 994 | 2.640 |
Why?
| | Machine Learning | 10 | 2024 | 517 | 2.630 |
Why?
| | Computational Biology | 20 | 2025 | 650 | 2.590 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.220 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1236 | 2.220 |
Why?
| | Metabolomics | 9 | 2022 | 692 | 2.170 |
Why?
| | Biometry | 13 | 2011 | 68 | 2.100 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 1048 | 1.830 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 17 | 1.750 |
Why?
| | Eye Proteins | 6 | 2016 | 92 | 1.690 |
Why?
| | Software | 15 | 2025 | 667 | 1.690 |
Why?
| | Neoplasms | 25 | 2024 | 2701 | 1.680 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.450 |
Why?
| | Regression Analysis | 13 | 2021 | 1015 | 1.450 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.430 |
Why?
| | Genomics | 12 | 2024 | 804 | 1.330 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1030 | 1.300 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 433 | 1.300 |
Why?
| | Models, Biological | 14 | 2021 | 1815 | 1.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1388 | 1.270 |
Why?
| | Humans | 196 | 2025 | 138651 | 1.200 |
Why?
| | Biomarkers | 14 | 2021 | 4111 | 1.130 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 431 | 1.130 |
Why?
| | Causality | 4 | 2022 | 128 | 1.120 |
Why?
| | Databases, Factual | 12 | 2024 | 1399 | 1.120 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1285 | 1.090 |
Why?
| | Insecticides | 4 | 2023 | 42 | 1.070 |
Why?
| | Biostatistics | 3 | 2014 | 18 | 1.060 |
Why?
| | Insect Control | 4 | 2023 | 18 | 1.060 |
Why?
| | Insect Vectors | 4 | 2023 | 38 | 1.050 |
Why?
| | Aromatase | 2 | 2019 | 32 | 1.000 |
Why?
| | Bangladesh | 13 | 2024 | 56 | 0.990 |
Why?
| | Survival Analysis | 12 | 2024 | 1313 | 0.990 |
Why?
| | Endemic Diseases | 2 | 2024 | 34 | 0.990 |
Why?
| | Natural Gas | 1 | 2025 | 25 | 0.910 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 32 | 0.910 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 186 | 0.910 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 290 | 0.890 |
Why?
| | Microscopy | 3 | 2023 | 155 | 0.860 |
Why?
| | Magnetoencephalography | 2 | 2021 | 154 | 0.850 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.840 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 252 | 0.840 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.820 |
Why?
| | Environmental Exposure | 3 | 2025 | 568 | 0.800 |
Why?
| | Genetic Association Studies | 5 | 2019 | 373 | 0.790 |
Why?
| | Models, Genetic | 11 | 2019 | 590 | 0.780 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1497 | 0.780 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 288 | 0.780 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2531 | 0.780 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.770 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 325 | 0.750 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 390 | 0.750 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.730 |
Why?
| | Connectome | 2 | 2021 | 87 | 0.730 |
Why?
| | Mass Spectrometry | 6 | 2022 | 741 | 0.710 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.700 |
Why?
| | Brain | 4 | 2024 | 2782 | 0.700 |
Why?
| | Brain Mapping | 2 | 2021 | 524 | 0.700 |
Why?
| | Housing | 2 | 2021 | 142 | 0.680 |
Why?
| | Nitriles | 1 | 2021 | 178 | 0.670 |
Why?
| | Endpoint Determination | 2 | 2011 | 78 | 0.670 |
Why?
| | Propensity Score | 4 | 2018 | 312 | 0.660 |
Why?
| | Cluster Analysis | 12 | 2024 | 515 | 0.660 |
Why?
| | Feasibility Studies | 2 | 2024 | 970 | 0.660 |
Why?
| | Phenotype | 12 | 2023 | 3160 | 0.640 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1033 | 0.640 |
Why?
| | Image Processing, Computer-Assisted | 7 | 2024 | 755 | 0.630 |
Why?
| | Placenta | 2 | 2019 | 752 | 0.630 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 157 | 0.620 |
Why?
| | Risk Assessment | 8 | 2020 | 3459 | 0.620 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 324 | 0.620 |
Why?
| | Learning | 1 | 2023 | 418 | 0.620 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 111 | 0.620 |
Why?
| | Databases, Genetic | 11 | 2021 | 241 | 0.610 |
Why?
| | Genetic Variation | 4 | 2019 | 1003 | 0.600 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 123 | 0.600 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 178 | 0.590 |
Why?
| | Metabolome | 1 | 2021 | 354 | 0.570 |
Why?
| | Transcriptome | 2 | 2023 | 970 | 0.560 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2055 | 0.550 |
Why?
| | Glioma | 1 | 2022 | 403 | 0.550 |
Why?
| | Protein Conformation | 4 | 2015 | 944 | 0.550 |
Why?
| | Logistic Models | 12 | 2020 | 2088 | 0.550 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1486 | 0.540 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3311 | 0.540 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 95 | 0.530 |
Why?
| | Male | 73 | 2025 | 68216 | 0.520 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1732 | 0.510 |
Why?
| | Registries | 2 | 2024 | 2051 | 0.490 |
Why?
| | Markov Chains | 7 | 2017 | 126 | 0.480 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1958 | 0.470 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 159 | 0.470 |
Why?
| | Linear Models | 7 | 2018 | 856 | 0.470 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 481 | 0.460 |
Why?
| | Empirical Research | 2 | 2012 | 22 | 0.450 |
Why?
| | Bayes Theorem | 7 | 2022 | 412 | 0.450 |
Why?
| | Female | 59 | 2025 | 73913 | 0.440 |
Why?
| | Case-Control Studies | 10 | 2025 | 3581 | 0.440 |
Why?
| | Protein Folding | 1 | 2016 | 279 | 0.440 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 90 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 646 | 0.430 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 403 | 0.430 |
Why?
| | Lupus Nephritis | 2 | 2025 | 65 | 0.430 |
Why?
| | Nerve Net | 3 | 2024 | 268 | 0.420 |
Why?
| | Statistics as Topic | 3 | 2025 | 299 | 0.420 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 108 | 0.410 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1398 | 0.410 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1108 | 0.410 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 166 | 0.400 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 170 | 0.400 |
Why?
| | India | 6 | 2023 | 197 | 0.390 |
Why?
| | Bias | 5 | 2022 | 224 | 0.390 |
Why?
| | Treatment Outcome | 9 | 2023 | 10938 | 0.390 |
Why?
| | Disease Progression | 15 | 2021 | 2734 | 0.390 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 51 | 0.380 |
Why?
| | Oncogenes | 1 | 2013 | 118 | 0.370 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 188 | 0.360 |
Why?
| | Animals | 33 | 2025 | 37309 | 0.360 |
Why?
| | Genome | 5 | 2017 | 299 | 0.350 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 525 | 0.350 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 6 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2513 | 0.350 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 602 | 0.350 |
Why?
| | Alzheimer Disease | 3 | 2015 | 570 | 0.340 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 18 | 0.330 |
Why?
| | Adenocarcinoma | 4 | 2017 | 882 | 0.330 |
Why?
| | Precision Medicine | 2 | 2025 | 419 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2143 | 0.330 |
Why?
| | Child, Preschool | 9 | 2025 | 11130 | 0.330 |
Why?
| | Models, Neurological | 2 | 2024 | 248 | 0.320 |
Why?
| | Antioxidants | 1 | 2014 | 593 | 0.320 |
Why?
| | Gene Expression | 3 | 2014 | 1494 | 0.320 |
Why?
| | Colorado | 6 | 2025 | 4528 | 0.320 |
Why?
| | Stem Cells | 3 | 2020 | 598 | 0.310 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 270 | 0.310 |
Why?
| | Signal Transduction | 10 | 2025 | 5091 | 0.310 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 110 | 0.310 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 28 | 0.310 |
Why?
| | Gene Dosage | 1 | 2010 | 142 | 0.310 |
Why?
| | Aged | 29 | 2024 | 24182 | 0.300 |
Why?
| | Risk Factors | 14 | 2025 | 10398 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 135 | 0.300 |
Why?
| | Middle Aged | 34 | 2024 | 33792 | 0.290 |
Why?
| | Child | 16 | 2025 | 21883 | 0.290 |
Why?
| | Liver Neoplasms | 1 | 2015 | 761 | 0.290 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 291 | 0.290 |
Why?
| | Proteomics | 5 | 2009 | 1113 | 0.290 |
Why?
| | Protein Array Analysis | 8 | 2009 | 56 | 0.290 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.290 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.280 |
Why?
| | Emigration and Immigration | 1 | 2008 | 50 | 0.280 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 668 | 0.280 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.280 |
Why?
| | Probability | 3 | 2021 | 309 | 0.280 |
Why?
| | Chromosome Mapping | 6 | 2017 | 515 | 0.280 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 326 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1476 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 637 | 0.270 |
Why?
| | Research Design | 5 | 2021 | 1120 | 0.260 |
Why?
| | Flow Cytometry | 2 | 2022 | 1197 | 0.260 |
Why?
| | Tumor Burden | 1 | 2008 | 307 | 0.260 |
Why?
| | Proteome | 3 | 2007 | 471 | 0.250 |
Why?
| | Adult | 27 | 2024 | 38296 | 0.250 |
Why?
| | Pancreas | 2 | 2020 | 325 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 256 | 0.250 |
Why?
| | Monte Carlo Method | 4 | 2017 | 141 | 0.240 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1055 | 0.240 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 204 | 0.240 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 27 | 0.230 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1376 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2474 | 0.230 |
Why?
| | False Positive Reactions | 4 | 2012 | 125 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 541 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 98 | 0.230 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 510 | 0.230 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2162 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 611 | 0.220 |
Why?
| | Replication Origin | 1 | 2004 | 21 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2368 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3642 | 0.220 |
Why?
| | Fever | 2 | 2023 | 306 | 0.220 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 67 | 0.220 |
Why?
| | Dengue Virus | 1 | 2024 | 52 | 0.210 |
Why?
| | Weather | 1 | 2024 | 40 | 0.210 |
Why?
| | Adolescent | 12 | 2025 | 21528 | 0.210 |
Why?
| | Data Curation | 1 | 2024 | 17 | 0.210 |
Why?
| | Leukemia | 1 | 2006 | 241 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2007 | 739 | 0.210 |
Why?
| | ROC Curve | 5 | 2020 | 566 | 0.210 |
Why?
| | Antigens | 1 | 2005 | 356 | 0.210 |
Why?
| | Ligands | 2 | 2016 | 665 | 0.210 |
Why?
| | Dengue | 1 | 2024 | 81 | 0.210 |
Why?
| | Melanoma | 3 | 2005 | 766 | 0.200 |
Why?
| | Cell Phone | 1 | 2024 | 75 | 0.200 |
Why?
| | Histones | 4 | 2020 | 637 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1065 | 0.200 |
Why?
| | Sample Size | 3 | 2008 | 125 | 0.200 |
Why?
| | Coculture Techniques | 1 | 2004 | 241 | 0.200 |
Why?
| | Staining and Labeling | 1 | 2023 | 155 | 0.200 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 30 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 1102 | 0.200 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 153 | 0.200 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.200 |
Why?
| | Carcinogens | 1 | 2003 | 126 | 0.200 |
Why?
| | Organometallic Compounds | 1 | 2023 | 112 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 174 | 0.190 |
Why?
| | Personality | 1 | 2004 | 130 | 0.190 |
Why?
| | Retina | 2 | 2016 | 303 | 0.190 |
Why?
| | Emphysema | 1 | 2023 | 108 | 0.190 |
Why?
| | Social Stigma | 1 | 2024 | 143 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 276 | 0.190 |
Why?
| | Biomedical Research | 2 | 2025 | 699 | 0.190 |
Why?
| | Neuroimaging | 2 | 2015 | 263 | 0.190 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2294 | 0.190 |
Why?
| | Parasites | 1 | 2022 | 49 | 0.180 |
Why?
| | Estrogens | 2 | 2019 | 369 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1239 | 0.180 |
Why?
| | Construction Materials | 1 | 2021 | 16 | 0.180 |
Why?
| | Infant | 3 | 2024 | 9565 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2703 | 0.180 |
Why?
| | Brain Waves | 1 | 2021 | 33 | 0.180 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.180 |
Why?
| | Young Adult | 11 | 2024 | 13322 | 0.180 |
Why?
| | Zebrafish | 2 | 2016 | 501 | 0.180 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 554 | 0.180 |
Why?
| | Analysis of Variance | 4 | 2024 | 1320 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 636 | 0.170 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 50 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 183 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1454 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 239 | 0.170 |
Why?
| | Epilepsy | 2 | 2021 | 337 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2016 | 342 | 0.170 |
Why?
| | Receptors, Androgen | 2 | 2021 | 150 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1873 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 375 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 102 | 0.170 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 224 | 0.170 |
Why?
| | Peptides | 4 | 2007 | 984 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 291 | 0.170 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 73 | 0.160 |
Why?
| | RNA, Messenger | 8 | 2024 | 2817 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 399 | 0.160 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 102 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 114 | 0.160 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 155 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 846 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 189 | 0.160 |
Why?
| | Androgens | 3 | 2012 | 186 | 0.160 |
Why?
| | Exome | 2 | 2018 | 235 | 0.160 |
Why?
| | Phosphorylation | 3 | 2019 | 1770 | 0.160 |
Why?
| | Hospital Mortality | 1 | 2024 | 916 | 0.160 |
Why?
| | Protein Binding | 5 | 2019 | 2236 | 0.150 |
Why?
| | Tretinoin | 1 | 2020 | 122 | 0.150 |
Why?
| | Disease Reservoirs | 1 | 2019 | 25 | 0.150 |
Why?
| | Artificial Intelligence | 3 | 2008 | 294 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 556 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 855 | 0.150 |
Why?
| | Mice | 16 | 2025 | 17848 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4015 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 42 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 59 | 0.150 |
Why?
| | Disease | 1 | 2019 | 100 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 26 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 67 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2602 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2928 | 0.150 |
Why?
| | Pilot Projects | 2 | 2021 | 1757 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 94 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2020 | 166 | 0.140 |
Why?
| | Pituitary Gland | 2 | 2009 | 149 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 62 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 460 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 864 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 708 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2022 | 314 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 345 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 114 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 87 | 0.140 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 856 | 0.140 |
Why?
| | Intensive Care Units | 1 | 2024 | 861 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 118 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 40 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 572 | 0.140 |
Why?
| | Pregnancy | 5 | 2019 | 6836 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 79 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 626 | 0.140 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 22 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 158 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 94 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5523 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 96 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 197 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 668 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 140 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 159 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 851 | 0.130 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1462 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 170 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2017 | 192 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 269 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 78 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 5 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 43 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 2 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 5 | 0.130 |
Why?
| | RNA, Viral | 2 | 2024 | 689 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 641 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 21 | 0.130 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 158 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 257 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2019 | 495 | 0.130 |
Why?
| | Mosquito Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 37 | 0.130 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 949 | 0.130 |
Why?
| | Transcription Factors | 6 | 2017 | 1707 | 0.120 |
Why?
| | Oxides | 1 | 2016 | 47 | 0.120 |
Why?
| | Anus Neoplasms | 1 | 2016 | 34 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2012 | 613 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 463 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 22 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 376 | 0.120 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 25 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 216 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 109 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 405 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 358 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 581 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 903 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | Anesthesiologists | 1 | 2016 | 38 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 91 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 191 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 375 | 0.120 |
Why?
| | Aged, 80 and over | 13 | 2022 | 7683 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 102 | 0.120 |
Why?
| | Cough | 2 | 2007 | 125 | 0.120 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1302 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 377 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2021 | 546 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 333 | 0.120 |
Why?
| | Oleic Acid | 1 | 2015 | 41 | 0.120 |
Why?
| | Proteolysis | 1 | 2016 | 176 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 304 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 377 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 3998 | 0.120 |
Why?
| | HIV Infections | 3 | 2022 | 2944 | 0.110 |
Why?
| | Air Pollution | 2 | 2017 | 315 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 451 | 0.110 |
Why?
| | Risk | 1 | 2017 | 912 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 396 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2190 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 803 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 2000 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 289 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 700 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.110 |
Why?
| | Time Factors | 5 | 2016 | 6877 | 0.110 |
Why?
| | Ants | 1 | 2014 | 27 | 0.110 |
Why?
| | Catalysis | 2 | 2012 | 318 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 452 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 13 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2019 | 529 | 0.110 |
Why?
| | Survival Rate | 4 | 2019 | 1932 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 350 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 53 | 0.110 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3406 | 0.110 |
Why?
| | Benzothiazoles | 1 | 2014 | 35 | 0.110 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 86 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2838 | 0.110 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 16 | 0.110 |
Why?
| | Chromatography, Gel | 1 | 2014 | 129 | 0.110 |
Why?
| | Amphotericin B | 1 | 2013 | 33 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 87 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 233 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 147 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 147 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1084 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 129 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 395 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5729 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 608 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5160 | 0.100 |
Why?
| | Estradiol | 2 | 2014 | 525 | 0.100 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.100 |
Why?
| | Interleukin-2 | 2 | 2025 | 451 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 302 | 0.090 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2024 | 102 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 78 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1261 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 9 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 78 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 912 | 0.090 |
Why?
| | Silver | 1 | 2012 | 38 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 423 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1083 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 865 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 198 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1162 | 0.090 |
Why?
| | Motion | 1 | 2012 | 98 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 13 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 981 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 16 | 0.090 |
Why?
| | Heme | 1 | 2012 | 77 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 92 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 13 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 11 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 99 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 996 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 680 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 349 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 103 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 231 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 228 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 165 | 0.090 |
Why?
| | Lung | 2 | 2023 | 4086 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3274 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 501 | 0.080 |
Why?
| | Chemokines | 1 | 2011 | 227 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1074 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 848 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1091 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 147 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 88 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1435 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1079 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 579 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Prevalence | 2 | 2015 | 2744 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 419 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 299 | 0.080 |
Why?
| | Autoimmunity | 2 | 2025 | 901 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.080 |
Why?
| | CpG Islands | 2 | 2023 | 159 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 87 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.070 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 128 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 960 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 95 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 54 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15860 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 203 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 109 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 649 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 837 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 33 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 44 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 130 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 336 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1598 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 689 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 89 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 234 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1014 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 384 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 31 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 48 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1310 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 189 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 326 | 0.070 |
Why?
| | Nails | 1 | 2007 | 13 | 0.070 |
Why?
| | Self Concept | 1 | 2009 | 256 | 0.070 |
Why?
| | Exercise | 1 | 2018 | 2074 | 0.060 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 118 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1310 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3628 | 0.060 |
Why?
| | Nepal | 2 | 2016 | 30 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2006 | 140 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 418 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 76 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 61 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 120 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 336 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 41 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 63 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 63 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 569 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 31 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 615 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 33 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2558 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 25 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 146 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 42 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 51 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 376 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 190 | 0.060 |
Why?
| | United States | 7 | 2018 | 15018 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 167 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 393 | 0.060 |
Why?
| | Family Characteristics | 2 | 2016 | 192 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 101 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 59 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 106 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 704 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 365 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 315 | 0.060 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 160 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 674 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 373 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1049 | 0.050 |
Why?
| | Poisson Distribution | 1 | 2004 | 75 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 260 | 0.050 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 18 | 0.050 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 21 | 0.050 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1889 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 304 | 0.050 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 60 | 0.050 |
Why?
| | Culture Techniques | 1 | 2004 | 73 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 43 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 166 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 366 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 384 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 167 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2385 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 512 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 59 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 68 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 875 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 141 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 209 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 425 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1637 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 42 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 64 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 326 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 135 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 828 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 68 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 83 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1437 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 290 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1545 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 100 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 131 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 176 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 317 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 137 | 0.050 |
Why?
| | Breast | 1 | 2003 | 158 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 856 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 39 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 132 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 321 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 139 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 715 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2219 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 249 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 388 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 127 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1153 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 100 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5812 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 188 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 31 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 53 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 290 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 176 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 41 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 132 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1102 | 0.040 |
Why?
| | Seasons | 1 | 2024 | 538 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 25 | 0.040 |
Why?
| | Entropy | 1 | 2021 | 40 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 38 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 417 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2045 | 0.040 |
Why?
| | Japan | 1 | 2021 | 128 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 563 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 457 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 518 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 153 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 394 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 202 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 41 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 58 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 25 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 35 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 270 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 903 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 570 | 0.040 |
Why?
| | Policy | 1 | 2021 | 149 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 553 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 38 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 66 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 270 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 236 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 309 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 94 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 509 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 138 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 13 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 16 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 2954 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 22 | 0.040 |
Why?
| | Skin | 2 | 2017 | 753 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 444 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4333 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 24 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1318 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 350 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 98 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 719 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 789 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 331 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 434 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 220 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 266 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 247 | 0.040 |
Why?
| | Malaria | 1 | 2019 | 64 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 647 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 856 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 432 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.030 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 41 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 423 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 237 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 289 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 176 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1480 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3038 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 48 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 596 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 44 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 85 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 1002 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 123 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 210 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 73 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 17 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 13 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 16 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 137 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 96 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 86 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 65 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 174 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 166 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 500 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 377 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 97 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 850 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 51 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 204 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 280 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 309 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 732 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 196 | 0.030 |
Why?
| | Family | 1 | 2019 | 677 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1176 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 166 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 310 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 972 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5594 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 69 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1053 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 200 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 138 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 316 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 854 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 341 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 99 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 663 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 27 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 228 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 44 | 0.030 |
Why?
| | North America | 1 | 2014 | 311 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 440 | 0.030 |
Why?
| | Demography | 1 | 2014 | 296 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 310 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 118 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 582 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 190 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2874 | 0.020 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 90 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 413 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2084 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 827 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2103 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 92 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 146 | 0.020 |
Why?
| | Methane | 1 | 2012 | 48 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 98 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 38 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 75 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 769 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 237 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 320 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7639 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 250 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 839 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1465 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1287 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 32 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2405 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 692 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 375 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1734 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 38 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 376 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 50 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 321 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 309 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 119 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2161 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1748 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 29 | 0.020 |
Why?
| | Genes | 1 | 2008 | 229 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 330 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 252 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 31 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 509 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 48 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 173 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 251 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 449 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 25 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 399 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 967 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 45 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 28 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1326 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 224 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 55 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 32 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 30 | 0.020 |
Why?
| | Television | 1 | 2007 | 75 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 817 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 89 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 229 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1101 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 140 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 111 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 188 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 78 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 84 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5868 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 96 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 165 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1248 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1358 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 523 | 0.010 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1368 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 60 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 69 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 78 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 51 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 58 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 369 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 94 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 43 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 56 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 41 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 364 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 430 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 207 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 149 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 351 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 96 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 268 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 27 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 19 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 81 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 571 | 0.010 |
Why?
| | Internet | 1 | 2007 | 674 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 67 | 0.010 |
Why?
| | California | 1 | 2003 | 441 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 598 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 192 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 206 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 560 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 623 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1655 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 942 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 897 | 0.010 |
Why?
| | RNA | 1 | 2005 | 928 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2039 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1137 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1859 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|